North America Liquid Biopsy Market

Market Introduction

Liquid biopsy is a revolutionary technology that is opening up various perspectives. The technology consists of isolation and detection of circulating tumor cells, circulating tumor DNA and exosomes, which provides genomic information of the cancer patients. Liquid biopsy are used in cancer diagnosis in order to study response or resistance to given treatments.

Moreover, in the United States, due to an increasing number of infected patients, healthcare professionals and leading organizations are distracting the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation. Furthermore, the pandemic spread is also preventing the clinical trials, drug development, and diagnostic industry in the US. For instance, California-based Lucence Diagnostics Pte Ltd., who develops liquid biopsy and has a known player in this industry, has been diverted now to manufacture kits for COVID-19.

Market Overview and Dynamics

The North America liquid biopsy market is expected to reach US$ 3,531.44 Mn in 2027 from US$ 1,522.58 Mn in 2018. The market is anticipated to grow with a CAGR of 10.1% from 2019-2027. Factors driving the market growth include increasing prevalence of cancer. However, low sensitivity of liquid biopsy is likely to have a negative impact on market growth.

Key Market Segments

By product & services, the reagents and kits segment accounted for the largest market share in the North American liquid biopsy market in 2018. In terms of sample, the blood based segment held the largest market share of the liquid biopsy market by 2027. By circulating biomarker, the circulating tumor cells (CTC) segment accounted for the largest market share in the North American liquid biopsy market in 2019. By 2027, the oncology segment accounted for the largest market share by application. Furthermore, in terms of end user, the reference laboratories segment held the largest market share of the liquid biopsy market by 2027.

Major Sources and Companies Listed

Some of the major primary and secondary sources for liquid biopsy market included in the report are, American Cancer Society (ACR), Centers For Disease Control And Prevention (CDC), Food and Drug Administration (FDA), International Diabetes Federation (IDF), and among others.

Reasons to buy the report

• To understand the liquid biopsy market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for liquid biopsy market
• Efficiently plan M&A and partnership deals in liquid biopsy market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form liquid biopsy market
• Obtain market revenue forecast for market by various segments from 2018-2027 in North America region.

NORTH AMERICA LIQUID BIOPSY MARKET SEGMENTATION

By Product & Service

• Equipment
• Reagents & Kits
• Services

By Sample

• Blood Based
• Urine Based
• Other samples

By Circulating Biomarker

• Circulating Tumor Cells (CTC)
• Exosomes
• Free Nucleic Acid

By Application

• Noninvasive Prenatal Testing (NIPT)
• Oncology
• Transplant Diagnostics
• Other Applications

By End User

• Academic & Research Institutes
• Hospitals
• Reference Laboratories
• Other End Users

By Geography

•             North America

• US
• Canada
• Mexico

Company Profiles

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Exact Sciences Corporation
• Biocept, Inc
• Inivata Ltd

North America Liquid Biopsy Market Strategic Insights

North America Liquid Biopsy Market Segmentation Analysis

North America Liquid Biopsy Market Report Highlights

North America Liquid Biopsy Report Scope

North America Liquid Biopsy Market Country and Regional Insights